Ex-Mer­ri­mack CEO Mul­roy launch­es on­col­o­gy start­up Part­ner Ther­a­peu­tics

Two vet­er­ans in this busi­ness — the for­mer Mer­ri­mack CEO and the ex-CMO of Ser­agon — have launched a new can­cer start­up that’s built on an in­creas­ing­ly pop­u­lar busi­ness mod­el in biotech: fill the C-suite first, then the pipeline.

The new ven­ture is called Part­ner Ther­a­peu­tics, or PTx, and it’s led by Robert Mul­roy, who re­signed as Mer­ri­mack’s CEO in Oc­to­ber 2016. Al­so at the helm is De­ba­sish Roy­chowd­hury, who’s serv­ing as PTx’s CMO. You might re­mem­ber Roy­chowd­hury from his time as CMO of Ser­agon Phar­ma­ceu­ti­cals, the com­pa­ny Roche/Genen­tech ac­quired for $725 mil­lion back in 2014. But Roy­chowd­hury al­so has a long re­sume in phar­ma, pre­vi­ous­ly serv­ing as clin­i­cal de­vel­op­ment VP at GSK, head­ing Sanofi’s on­col­o­gy unit, and lead­ing the glob­al on­col­o­gy reg­u­la­to­ry group at Eli Lil­ly.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER